-
National Institute of Neurological Disorders and Stroke. Know stroke. Know the signs. Act in time. National Institute of Neurological Disorders and Stroke website. http://www.ninds.nih.gov/disorders/stroke/knowstroke.htm.Last modified March 29, 2016. Accessed August 12, 2016.
National Institute of Neurological Disorders and Stroke. Know stroke. Know the signs. Act in time. National Institute of Neurological Disorders and Stroke website. http://www.ninds.nih.gov/disorders/stroke/knowstroke.htm.Last modified March 29, 2016. Accessed August 12, 2016.
-
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2019;50:e344-e418.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2019;50:e344-e418.
-
Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2016;47(2):581-641.
Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2016;47(2):581-641.
-
Ferbert A, Brückmann H, Drummen R. Clinical features of proven basilar artery occlusion.Stroke.1990;21(8):1135-1142. doi:10.1161/01.str.21.8.1135
Ferbert A, Brückmann H, Drummen R. Clinical features of proven basilar artery occlusion.Stroke.1990;21(8):1135-1142. doi:10.1161/01.str.21.8.1135
-
Kattah JC, Talkad AV, Wang DZ, et al. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging.Stroke. 2009;40(11):3504-10.
Kattah JC, Talkad AV, Wang DZ, et al. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging.Stroke. 2009;40(11):3504-10.
-
Activase [prescribing information]. South San Francisco, CA: Genentech, Inc.
Activase [prescribing information]. South San Francisco, CA: Genentech, Inc.
-
Arch AE, Weisman DC, Coca S, et al. Missed ischemic stroke diagnosis in the emergency department by emergency medicine and neurology services.Stroke. 2016;47(3):668-73.
Arch AE, Weisman DC, Coca S, et al. Missed ischemic stroke diagnosis in the emergency department by emergency medicine and neurology services.Stroke. 2016;47(3):668-73.
-
Madsen TE, Khoury J, Cadena R, et al. Potentially missed diagnosis of ischemic stroke in the emergency department in the Greater Cincinnati/Northern Kentucky stroke study.Academic Emergency Medicine. 2016;23(10):1128-35.
Madsen TE, Khoury J, Cadena R, et al. Potentially missed diagnosis of ischemic stroke in the emergency department in the Greater Cincinnati/Northern Kentucky stroke study.Academic Emergency Medicine. 2016;23(10):1128-35.
-
Masoud HE, de Havenon A, Castonguay AC et al. 2022 brief practice update on intravenous thrombolysis before thrombectomy in patients with large vessel occlusion acute ischemic stroke: a statement from Society of Vascular and Interventional Neurology Guidelines and Practice Standards (GAPS) committee.Stroke Vasc Interv Neurol. 2022;2:e000276. doi:10.1161/SVIN.121.000276
Masoud HE, de Havenon A, Castonguay AC et al. 2022 brief practice update on intravenous thrombolysis before thrombectomy in patients with large vessel occlusion acute ischemic stroke: a statement from Society of Vascular and Interventional Neurology Guidelines and Practice Standards (GAPS) committee.Stroke Vasc Interv Neurol. 2022;2:e000276. doi:10.1161/SVIN.121.000276
-
Trevo EDFU. Fremont, CA: Stryker International; 2016.
Trevo EDFU. Fremont, CA: Stryker International; 2016.
-
Solitaire Revascularization Device. Medtronic website. Updated February 2018. Accessed May 9, 2018. http://www.medtronic.com/us-en/healthcare-professionals/products/neurological/revascularization-stroke/solitaire.html
Solitaire Revascularization Device. Medtronic website. Updated February 2018. Accessed May 9, 2018. http://www.medtronic.com/us-en/healthcare-professionals/products/neurological/revascularization-stroke/solitaire.html
-
Food and Drug Administration. FDA information on medication errors involving Activase and TNKase. September 2015. Available at http://www.fda.gov. Accessed on February 24, 2023.
Food and Drug Administration. FDA information on medication errors involving Activase and TNKase. September 2015. Available at http://www.fda.gov. Accessed on February 24, 2023.
-
Data on file. Genentech USA. No Title.
Data on file. Genentech USA. No Title.
-
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.N Engl J Med. 1995;333:1581-1587.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.N Engl J Med. 1995;333:1581-1587.
-
FDA Access Summary basis of approval. https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/altegen061896s.pdf. Accessed August 14, 2017.
FDA Access Summary basis of approval. https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/altegen061896s.pdf. Accessed August 14, 2017.
-
Summers D, Leonard A, Wentworth D, et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association.Stroke. 2009;40:2911-2944.
Summers D, Leonard A, Wentworth D, et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association.Stroke. 2009;40:2911-2944.
-
American Association of Neuroscience Nurses. Reference Series for Clinical Practice. 2004. Available at https://aann.org/. Accessed on February 23, 2023.
American Association of Neuroscience Nurses. Reference Series for Clinical Practice. 2004. Available at https://aann.org/. Accessed on February 23, 2023.
-
Tamm A, Siddiqui M, Shuaib A, et al. Impact of stroke care unit on patient outcomes in a community hospital.Stroke. 2014;45(1):211-216.
Tamm A, Siddiqui M, Shuaib A, et al. Impact of stroke care unit on patient outcomes in a community hospital.Stroke. 2014;45(1):211-216.
-
CMS Quality Measurement Programs Characteristics. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/CMSQualityMeasurementProgramsCharacteristics.PDF. Published June 28, 2012. Accessed August 13, 2016.
CMS Quality Measurement Programs Characteristics. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/CMSQualityMeasurementProgramsCharacteristics.PDF. Published June 28, 2012. Accessed August 13, 2016.
-
The Joint Commission, Stroke. Last updated June 17, 2016. Accessed August 1, 2016. https://www.jointcommission.org/stroke/
The Joint Commission, Stroke. Last updated June 17, 2016. Accessed August 1, 2016. https://www.jointcommission.org/stroke/
-
Skolarus LE, Meurer WJ, Shanmugasundaram K, et al. Marked regional variation in acute stroke treatment among Medicare beneficiaries.Stroke. 2015;46:1890-1896.
Skolarus LE, Meurer WJ, Shanmugasundaram K, et al. Marked regional variation in acute stroke treatment among Medicare beneficiaries.Stroke. 2015;46:1890-1896.
-
ICD-10. https://www.cms.gov/Medicare/Coding/ICD10/.Accessed August 14, 2017.
ICD-10. https://www.cms.gov/Medicare/Coding/ICD10/.Accessed August 14, 2017.
-
Schwamm LH, Pancioli A, Acker JE, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems.Stroke. 2005;36(3):690-703.
Schwamm LH, Pancioli A, Acker JE, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems.Stroke. 2005;36(3):690-703.
-
Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative.Stroke. 2011;42(10):2983-2989.
Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative.Stroke. 2011;42(10):2983-2989.
-
Goyal M, Menon BK, Hill MD, Demchuk A. Consistently achieving computed tomography to endovascular recanalization <90 minutes: solutions and innovations.Stroke. 2014;45(12):e252-e256.
Goyal M, Menon BK, Hill MD, Demchuk A. Consistently achieving computed tomography to endovascular recanalization <90 minutes: solutions and innovations.Stroke. 2014;45(12):e252-e256.
-
Kalanithi L, Tai W, Conley J, Platchek T, Zulman D, Milstein A. Better health, less spending: delivery innovation for ischemic cerebrovascular disease. Stroke. 2014;45(10):3105-3111.
Kalanithi L, Tai W, Conley J, Platchek T, Zulman D, Milstein A. Better health, less spending: delivery innovation for ischemic cerebrovascular disease. Stroke. 2014;45(10):3105-3111.
-
Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months.Neurology. 2013;81(12):1071-1076.
Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months.Neurology. 2013;81(12):1071-1076.
-
Nguyen-Huynh MN. KPNC stroke EXPRESS: expediting the process of evaluating and stopping stroke. Presentation; 2016.
Nguyen-Huynh MN. KPNC stroke EXPRESS: expediting the process of evaluating and stopping stroke. Presentation; 2016.
-
American Heart Association. Target: Stroke. Accessed April 10, 2023. https://www.heart.org/en/professional/quality-improvement/target-stroke
American Heart Association. Target: Stroke. Accessed April 10, 2023. https://www.heart.org/en/professional/quality-improvement/target-stroke
-
Wechsler LR, Demaerschalk BM, Schwamm LH, et al. Telemedicine quality and outcomes in stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2017 Jan 1;48(1):e3-25.
Wechsler LR, Demaerschalk BM, Schwamm LH, et al. Telemedicine quality and outcomes in stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2017 Jan 1;48(1):e3-25.
-
American Hospital Association. http://www.aha.org/research/reports/tw/12oct-tw-quality.pdf.October 2012. Accessed October 11, 2016.
American Hospital Association. http://www.aha.org/research/reports/tw/12oct-tw-quality.pdf.October 2012. Accessed October 11, 2016.
-
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
-
Fesmire FM, Brown MD, Espinosa JA, et al. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism.Ann Emerg Med.2011 Jun;57(6):628-652.e75.
Fesmire FM, Brown MD, Espinosa JA, et al. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism.Ann Emerg Med.2011 Jun;57(6):628-652.e75.
-
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism.Chest. 2002;121:877-905.
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism.Chest. 2002;121:877-905.
-
Tan KT, Oudkerk M, van Beek EJR. Deep Vein Thrombosis and Pulmonary Embolism. In: Hallet JW Jr, Mills JL, Earnshaw JJ, Reekers JA, eds.Comprehensive Vascular and Endovascular Surgery. Philadelphia, PA: Elsevier Limited; 2003.
Tan KT, Oudkerk M, van Beek EJR. Deep Vein Thrombosis and Pulmonary Embolism. In: Hallet JW Jr, Mills JL, Earnshaw JJ, Reekers JA, eds.Comprehensive Vascular and Endovascular Surgery. Philadelphia, PA: Elsevier Limited; 2003.
-
Martin-Schild S, Albright KC, Tanksley J, et al. Zero on the NIHSS does not equal the absence of stroke.Ann Emerg Med. 2011;57:42-45.
Martin-Schild S, Albright KC, Tanksley J, et al. Zero on the NIHSS does not equal the absence of stroke.Ann Emerg Med. 2011;57:42-45.
-
NIH Stroke Scale International. Approach to Human Subject Protection and Patient Safety. Available at: http://www.nihstrokescale.org. Accessed March 18, 2020.
NIH Stroke Scale International. Approach to Human Subject Protection and Patient Safety. Available at: http://www.nihstrokescale.org. Accessed March 18, 2020.
-
Centers for Disease Control and Prevention.MMWR. 2009 May 1;58:421-426.
Centers for Disease Control and Prevention.MMWR. 2009 May 1;58:421-426.
-
Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.Stroke. 2012;43:2293-2299.
Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.Stroke. 2012;43:2293-2299.
-
Searls DE, Pazdera L, Korbel E, Vysata O,Caplan LR. Symptoms and signs of posterior circulation ischemia in the New England Medical Center posteriorcirculation registry. Arch Neurol. 2012;69(3):346-351. doi:10.1001/archneurol.2011.2083
Searls DE, Pazdera L, Korbel E, Vysata O,Caplan LR. Symptoms and signs of posterior circulation ischemia in the New England Medical Center posteriorcirculation registry. Arch Neurol. 2012;69(3):346-351. doi:10.1001/archneurol.2011.2083
FAQs
What is an AIS acute ischemic stroke? ›
An arterial ischemic stroke (AIS) occurs when blood flow in an artery to the brain is blocked by narrowing of the artery, or when a blood clot forms in the artery and blocks the supply of blood to a part of the brain.
What diagnostic test should always precede the administration of alteplase? ›*The American Heart Association/American Stroke Association recommends brain imaging (noncontrast CT in most cases) and assessment of blood glucose precede the initiation of IV alteplase in all patients.
How effective is alteplase? ›In the pooled analysis, treatment with alteplase is nearly twice as efficacious when administered within the first 1.5 hours after the onset of a stroke as it is when administered within 1.5 to 3 hours afterward (odds ratio for the global outcome, 2.81 for an interval of 0 to 90 minutes, 1.55 for 91 to 180 minutes, and ...
How effective is tPA for ischemic stroke? ›In 1995, results from this pivotal trial showed that patients treated with tPA within three hours of symptom onset were at least 30 percent more likely than placebo-treated patients to have minimal or no disability for up to three months.
What is the difference between acute ischemic stroke and ischemic stroke? ›Ischemic stroke (see the image below) is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. Acute ischemic stroke is caused by thrombotic or embolic occlusion of a cerebral artery and is more common than hemorrhagic stroke.
How serious is acute ischemic stroke? ›Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 700 000 people each year. The primary risk factor for acute ischemic stroke is high blood pressure.
What is the greatest concern with alteplase? ›Activase can cause significant, sometimes fatal internal or external bleeding, especially at arterial and venous puncture sites. Avoid intramuscular injections and trauma to the patient. Perform venipunctures carefully and only as required.
When not to use alteplase? ›Do not administer Activase to treat acute myocardial infarction or pulmonary embolism in the following situations in which the risk of bleeding is greater than the potential benefit: active internal bleeding; history of recent stroke; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; ...
What are the guidelines for alteplase? ›The total dose should not exceed 90 mg. Ten percent of the total dose gets administered as an intravenous (IV) bolus over 1 minute, and the infusion of the remainder occurs over 60 minutes. The administration should take place as soon as possible and within 4.5 hours of symptom onset.
How to know if alteplase is effective? ›The effectiveness of alteplase in an extended time window up to 4.5 hours is confirmed by evaluation of the data from the Safe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register (SITS-ISTR) registry which shows that the rates of sICH, mortality, and independence at three-month follow-up ...
What are the outcomes of alteplase for stroke? ›
The administration of alteplase within a time frame of up to four and a half hours following onset of symptoms has been shown to improve long-term outcomes in individuals suffering from stroke.
What are the disadvantages of alteplase? ›In addition, alteplase has disadvantages related to its short half-life, incomplete recanalization, high risk of intracranial hemorrhage (ICH), and long continuous infusion time, which limit its efficacy [8, 9].
Which is the initial diagnostic test for a stroke? ›A CT scan of the head is usually one of the first tests used for a stroke. A CT scan can show bleeding in the brain or damage to brain cells. The CT scan also can find other problems that can cause stroke symptoms. Magnetic resonance imaging (MRI).
What is the miracle drug for strokes? ›tPA quickly dissolves the clots that cause many strokes. By opening a blocked blood vessel and restoring blood flow, tPA can reduce the amount of damage to the brain that can occur during a stroke. To be effective, tPA and other drugs like it must be given within a few hours of the stroke symptoms beginning.
When not to give tPA for stroke? ›Relative Exclusion Criteria
Pregnancy. Seizure at the onset with postictal residual neurological impairments. Major surgery or serious trauma within prior 14 days. Recent GI or urinary tract hemorrhage (within previous 21 days)
When a focal symptomatic reversible ischemia occurs in the brain, it is called TIA, and when a focal symptomatic irreversible ischemia occurs in the brain, it is called AIS.
What are the symptoms of AIS stroke? ›- Sudden numbness or weakness of the face, arm or leg, especially on one side of the body.
- Sudden confusion.
- Sudden trouble speaking.
- Sudden trouble seeing in one or both eyes.
- Sudden trouble walking.
- Sudden dizziness, loss of balance or coordination.
- Sudden, severe headache with no known cause.
Intravenous Thrombolysis. As recommended by AHA/ASA intravenous tPA infusion is treatment modality of choice for patients presenting within first 3 hours of onset of symptoms.
Can you recover from an acute ischemic stroke? ›Each person has a different recovery time and need for long-term care. Problems with moving, thinking, and talking often improve in the first weeks or months after a stroke. Some people will keep improving months or years after a stroke.